Applikon to buy HaloteC’s biotech portfolio
Bioreactor systems vendor Applikon Biotechnology has arranged to acquire the biotech portfolio of Dutch instruments and software provider HaloteC Instruments.
Applikon CEO Arthur Oudshoorn said the company plans to use the HaloteC technology to augment its existing its bioreactor software offerings.
“Organisations are looking for software solutions to allow parallel processing of bioreactor systems and to process the large amount of data generated by these processes,” he said.
Oudshoorn added that the investment forms part of Applikon’s efforts to be able to provide an advanced data centre for biotech processes.
Terms of the transaction were not disclosed.
Applikon Biotechnology is headquartered in the Netherlands and in Belgium. In Australia and New Zealand, the company provides its products through its dedicated agent Enztech in New South Wales.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
